Jounce Therapeutics, Inc. (NasdaqGS: JNCE)
Health Care · Biotechnology · US
$—
— today · — 1Y
Jounce Therapeutics, Inc. (NasdaqGS: JNCE) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Jounce Therapeutics, Inc. across four factors: quality 48/100, value 64/100, growth 27/100. Its strongest factor is value.
JNCE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $82.00M
- P/E
- —
- EPS
- -0.99
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 141
- Next earnings
- —
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors. The company is also progressing JTX-8064, an antibody designed to target leukocyte immunoglobulin like receptor B2 (LILRB2), a cell surface receptor found on macrophages. Additionally, JTX-1484 is under development, focusing on myeloid targets. Completing its innovative portfolio is JTX-1811, an anti-CCR8 monoclonal antibody precisely engineered to selectively reduce the presence of intra-tumoral T regulatory cells within the tumor's microenvironment. Jounce Therapeutics, Inc. was founded in 2012 and maintains its primary operational base in Cambridge, Massachusetts.
- ISIN
- US4811161011
- Founded
- 2012
- Listed since
- Jan 26, 2017
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PhaseRx, Inc.OTCPK: PZRX.Q | $12.00 | $— | — |
| ContraFect CorporationOTCPK: CFRX.Q | $11.00 | $0.00 | — |
| Notable Labs, Ltd.OTCPK: NTBL.Q | $10.00 | $— | — |
| OncoSec Medical IncorporatedOTCPK: ONCS.Q | $6.00 | $0.00 | — |
| Calithera Biosciences, Inc.OTCPK: CALA | $5.00 | $0.00 | -99.00% |
| Biocept, Inc.OTCPK: BIOC.Q | $3.00 | $0.00 | -99.50% |
| Yield10 Bioscience, Inc.OTCPK: YTEN.Q | $1.00 | $— | — |
| LadRx CorporationOTCPK: LADX | $0.00 | $0.00 | -99.50% |
Figures last refreshed Oct 18, 2026.